...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction
【24h】

Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction

机译:药物干预预防心肌梗塞左心室重构和改善预后

获取原文
获取原文并翻译 | 示例

摘要

Early reperfusion of totally occluded coronary arteries with thrombolysis and/or percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) reduces infarct size, cardiac mortality, and in-hospital events. Prompt reperfusion of epicardial blood flow reduces infarct size and mortality rates, in-hospital events, and reinfarction. Furthermore, successful reperfusion greatly affects the reduction in infarct size and left ventricular (LV) function. The reduction in infarct size and the improvement in LV ejection fraction may decrease mechanical stress on the noninfarcted myocardium, preventing LV remodeling, including changes in LV size and shape. Preventing LV remodeling is of key importance after AMI because it may be related to a reduction in adverse cardiac events, including exacerbation of congestive heart failure and cardiac mortality rates. Although reperfusion therapy relieves and reduces ischemia and necrosis, the process of restoring coronary blood flow causes ischemia-reperfusion injury in the ischemic myocardium, which limits the beneficial effects of reperfusion and may contribute to mortality despite successful reperfusion therapy.Reperfusion injury is triggered by cellular and mitochondrialcalcium overload, oxidant stress, endothelial dysfunction, reduction in nitric oxide production, and other factors. Because reperfusion injury limits the efficacy of reperfusion therapy alone, combined use with pharmacological intervention may moderate microcirculatory impairment and clinical outcomes. Such treatments may eventually reduce infarction size and prevent ischemic LV remodeling after AMI. Furthermore, medication in the chronic phase may affect LV remodeling and clinical prognoses. We undertook a systematic review of the literature based on pharmacological reductions in infarct size and prevention of LV remodeling, both of which may be associated with improved clinical outcomes, in cases of MI. In this review, searches through MEDLINE, LILACS, and SCIELO were the sources of information. Articles were selected by their content related to the theme.The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
机译:通过溶栓和/或经皮冠状动脉介入治疗(PCI)对急性心肌梗死(AMI)进行早期完全灌注冠状动脉再灌注,可减少梗塞面积,心脏死亡率和住院事件。及时再灌注心外膜血流可减少梗死面积和死亡率,住院事件和再梗塞。此外,成功的再灌注极大地影响了梗死面积的缩小和左心室(LV)功能。梗塞面积的减少和左室射血分数的改善可以减少非梗塞心肌的机械应力,防止左室重构,包括左室尺寸和形状的改变。预防AMI后左室重塑至关重要,因为它可能与不良心脏事件(包括充血性心力衰竭和心脏死亡率的恶化)的减少有关。尽管再灌注疗法可以缓解和减少缺血和坏死,但恢复冠状动脉血流的过程会导致缺血心肌的缺血再灌注损伤,从而限制了再灌注的有益作用,尽管再灌注疗法成功了也可能导致死亡。线粒体钙超载,氧化应激,内皮功能障碍,一氧化氮生成减少等因素。由于再灌注损伤仅限制了再灌注治疗的功效,因此与药物干预措施结合使用可缓解微循环障碍和临床结局。此类治疗可最终减少梗死面积并防止AMI后缺血性LV重塑。此外,慢性期用药可能会影响左室重塑和临床预后。我们对基于梗塞面积的药理学减少和预防左室重塑的文献进行了系统的回顾,在发生MI的情况下,这两者均可能与改善临床预后有关。在这篇评论中,通过MEDLINE,LILACS和SCIELO进行的搜索是信息的来源。文章是根据其与主题相关的内容进行选择的。作者有权完全访问数据并承担数据完整性的责任。所有作者均已阅读并同意所写的手稿。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号